scholarly journals Managing future Gulf War Syndromes: international lessons and new models of care

2006 ◽  
Vol 361 (1468) ◽  
pp. 707-720 ◽  
Author(s):  
Charles C Engel ◽  
Kenneth C Hyams ◽  
Ken Scott

After the 1991 Gulf War, veterans of the conflict from the United States, United Kingdom, Canada, Australia and other nations described chronic idiopathic symptoms that became popularly known as ‘Gulf War Syndrome’. Nearly 15 years later, some 250 million dollars in United States medical research has failed to confirm a novel war-related syndrome and controversy over the existence and causes of idiopathic physical symptoms has persisted. Wartime exposures implicated as possible causes of subsequent symptoms include oil well fire smoke, infectious diseases, vaccines, chemical and biological warfare agents, depleted uranium munitions and post-traumatic stress disorder. Recent historical analyses have identified controversial idiopathic symptom syndromes associated with nearly every modern war, suggesting that war typically sets into motion interrelated physical, emotional and fiscal consequences for veterans and for society. We anticipate future controversial war syndromes and maintain that a population-based approach to care can mitigate their impact. This paper delineates essential features of the model, describes its public health and scientific underpinnings and details how several countries are trying to implement it. With troops returning from combat in Afghanistan, Iraq and elsewhere, the model is already getting put to the test.

2004 ◽  
Vol 26 (4) ◽  
pp. 295-308 ◽  
Author(s):  
Hikmet Jamil ◽  
Sylvia C. Nassar-McMillan ◽  
Richard Lambert

Iraqi Gulf War (GW) veteran refugees, or those who fled the Hussein regime and were subsequently granted refugee stated by the United States, are at high risk for the same mental health maladies that afflict U.S. GW veterans. We conducted a pilot survey on a group of Iraqi GW veteran refugees to assess levels of post-traumatic stress disorder (PTSD), depression, panic, and anxiety. We hypothesized that significantly more participants with PTSD would report depression, panic, and anxiety symptoms than their non-PTSD counterparts. We further expected that those with PTSD would report significantly higher mean scores on depression, panic, and anxiety than those participants not identified as having PTSD. Results indicated high levels of each of the symptom categories among the PTSD groups. PTSD sufferers conjointly assessed with significantly elevated levels of depression and panic as compared to their non-PTSD counterparts.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hannah B. Elam ◽  
Stephanie M. Perez ◽  
Jennifer J. Donegan ◽  
Daniel J. Lodge

AbstractPost-traumatic stress disorder (PTSD) is a prevalent condition affecting approximately 8% of the United States population and 20% of United States combat veterans. In addition to core symptoms of the disorder, up to 64% of individuals diagnosed with PTSD experience comorbid psychosis. Previous research has demonstrated a positive correlation between symptoms of psychosis and increases in dopamine transmission. We have recently demonstrated projections from the paraventricular nucleus of the thalamus (PVT) to the nucleus accumbens (NAc) can regulate dopamine neuron activity in the ventral tegmental area (VTA). Specifically, inactivation of the PVT leads to a reversal of aberrant dopamine system function and psychosis-like behavior. The PVT receives dense innervation from orexin containing neurons, therefore, targeting orexin receptors may be a novel approach to restore dopamine neuron activity and alleviate PTSD-associated psychosis. In this study, we induced stress-related pathophysiology in male Sprague Dawley rats using an inescapable foot-shock procedure. We observed a significant increase in VTA dopamine neuron population activity, deficits in sensorimotor gating, and hyperresponsivity to psychomotor stimulants. Administration of selective orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) antagonists (SB334867 and EMPA, respectively) or the FDA-approved, dual-orexin receptor antagonist, Suvorexant, were found to reverse stress-induced increases in dopamine neuron population activity. However, only Suvorexant and SB334867 were able to reverse deficits in behavioral corelates of psychosis. These results suggest that the orexin system may be a novel pharmacological target for the treatment of comorbid psychosis related to PTSD.


Sign in / Sign up

Export Citation Format

Share Document